MONTREAL, Nov. 3 /PRNewswire/ -- Enobia Pharma announced today the initiation of a Phase 2 clinical study of ENB-0040, a bone-targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). The six-month study will assess the safety, efficacy and pharmacokinetics of ENB-0040 in up to 12 children with HPP. This study follows the recent presentation of positive Phase 2 data in infants, which showed that, in the majority of patients, six months of treatment with ENB-0040 led to marked improvements in bone mineralization, correction of skeletal defects, better respiratory function, and improvements in cognitive and motor development.
